Forte Biosciences (FBRX) EBITDA Margin (2017 - 2019)
Forte Biosciences (FBRX) posted quarterly EBITDA Margin of 17377.78% for Q4 2019, up 19493333.0% year-over-year from N/an in Q4 2018, and down 128.65% quarter-over-quarter from 7600.0% in Q3 2019.
Powered by 
Analysis
Forte Biosciences (FBRX) EBITDA Margin (2017 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported EBITDA Margin for 3 consecutive years, with 17377.78% the latest figure, recorded in Q4 2019.
- In Q4 2019, EBITDA Margin rose 19493333.0% year-over-year to 17377.78%; the TTM figure through Dec 2019 stood at 54855.56% (down 5460132.0% YoY), while the FY2019 annual figure was 11288.89%, down 1103466.0% from the prior year.
- EBITDA Margin retreated to 17377.78% in Q4 2019 per FBRX's latest filing, from 7600.0% in the prior quarter.
- Across five years, EBITDA Margin topped out at 7.92% in Q3 2018 and bottomed at 212311.11% in Q4 2018.
- Historically, EBITDA Margin has averaged 94138.07% across 3 years, with a median of 97370.0% in 2017.
- Annual changes were most pronounced in 2018 — EBITDA Margin tumbled 10544111 bps — and 2019, when it surged 19493333 bps.
- Forte Biosciences' EBITDA Margin stood at 106870.0% in 2017, then tumbled by 99 bps to 212311.11% in 2018, then soared by 92 bps to 17377.78% in 2019.
- Business Quant data shows FBRX's EBITDA Margin at 17377.78% in Q4 2019, 7600.0% in Q3 2019, and 6988.89% in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 19.75% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.36% |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -17,377.78% |
| Sep 30, 2019 | -7,600.00% |
| Jun 30, 2019 | -6,988.89% |
| Mar 31, 2019 | -187,455.56% |
| Dec 31, 2018 | -212,311.11% |
| Sep 30, 2018 | 7.92% |
| Jun 30, 2018 | -170,300.00% |
| Mar 31, 2018 | -142,733.33% |
| Dec 31, 2017 | -106,870.00% |
| Sep 30, 2017 | -97,370.00% |
| Jun 30, 2017 | -86,520.00% |